Solventum (NYSE:SOLV) Upgraded to Hold at Wells Fargo & Company

Solventum (NYSE:SOLV) was upgraded by equities research analysts at Wells Fargo & Company to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Other equities research analysts have also issued reports about the company. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. KeyCorp lifted their price objective on Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. BTIG Research restated a “buy” rating and set a $100.00 target price on shares of Solventum in a report on Friday, February 27th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.70.

Solventum Trading Down 2.2%

Shares of SOLV stock opened at $67.18 on Wednesday. The company has a market capitalization of $11.66 billion, a P/E ratio of 7.57, a P/E/G ratio of 1.13 and a beta of 0.40. Solventum has a 12-month low of $60.70 and a 12-month high of $88.20. The company has a quick ratio of 0.89, a current ratio of 1.23 and a debt-to-equity ratio of 1.00. The firm has a 50-day moving average price of $75.50 and a 200 day moving average price of $75.88.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. The firm had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.41 earnings per share. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Research analysts forecast that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its Board of Directors has approved a share buyback plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 7.5% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Solventum

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. The trade was a 41.39% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.05% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Solventum

Several hedge funds have recently added to or reduced their stakes in SOLV. Clifford Capital Partners LLC raised its stake in shares of Solventum by 3.1% during the second quarter. Clifford Capital Partners LLC now owns 269,790 shares of the company’s stock worth $20,461,000 after buying an additional 8,085 shares during the last quarter. Nordea Investment Management AB boosted its stake in Solventum by 3.5% in the third quarter. Nordea Investment Management AB now owns 758,847 shares of the company’s stock valued at $54,880,000 after acquiring an additional 25,987 shares during the last quarter. LSV Asset Management grew its holdings in Solventum by 364.5% during the 3rd quarter. LSV Asset Management now owns 35,122 shares of the company’s stock worth $2,564,000 after acquiring an additional 27,561 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Solventum by 15.3% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock worth $22,469,000 after acquiring an additional 40,812 shares during the period. Finally, Candriam S.C.A. raised its position in shares of Solventum by 48.6% during the 3rd quarter. Candriam S.C.A. now owns 80,975 shares of the company’s stock valued at $5,911,000 after acquiring an additional 26,481 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.